Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytopia strengthens scientific team

This article was originally published in Scrip

Executive Summary

Cytopia (Australia) has appointed Dr Devron Averett chief scientific advisor. He will work closely with the company's executive management team, on a part-time basis during this year, to provide scientific leadership and guidance. He has held leadership roles at Glaxo Wellcome and Burroughs Wellcome and, in recent years, at Valeant Pharmaceuticals International and Anadys Pharmaceuticals, a company he co-founded. Cytopia is also consolidating its North American operations in Woodside, California, and closing the Rensselaer, New York, office, which is currently led by Dr Shreefal Mehta as vice-president of business and corporate development. Dr Mehta has chosen not to relocate to the west coast and will leave the company at the end of July. Richard Haiduck, who has been working with the company in a strategic consulting role, has been appointed as chief business advisor, with responsibility for Cytopia's global business and corporate development.

You may also be interested in...



Commercial Partner Sought For Nasal Spray Claimed To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Russia Prepares $10 COVID-19 Vaccine For International Launch

Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.

Galapagos Sells CRO To Selvita For €31.2m

The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel